Corporate Magazine 2012 - Boehringer Ingelheim

FINDING THE RIGHT MOLECULE“Finding the right molecule”, a bookthat guides readers through theinnovative development journeyof pradaxa®.Find out more here:www.heartofstroke.commost reimbursement agencies have concludedthat pradaxa® is a cost-effectiveuse of health care resources.1 Mission 1 MillionIn cooperation with leading medicaland patient organisations, such as theWorld Heart Federation and the AtrialFibrillation Association, the 1 Mission1 Million initiative has continued toraise awareness of AF and its link tostroke around the world. Communitybasedaction is at the heart of this globalinitiative, and during 2012 thefoundations of phase 2 were launchedto ensure ongoing engagement in 2013with key stakeholders – patients,healthcare professionals and thirdparty groups.1 Mission 1 Million – three approaches• Supporting projects around the worldthat aim to help prevent AF-relatedstroke.• The petition calls upon people to helpsave lives from potentially disablingor fatal AF-related strokes. The globalpetition calls upon health organisationsaround to world to fully recogniseAF as a serious condition and asa risk factor for stroke through bettermanagement, stroke prevention andeducation.• Encouraging people directly affectedby AF to share their unique storiesand experiences.72Boehringer Ingelheim annual report 2012